A new mouse study conducted by scientists at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai has pointed to another way that checkpoint inhibitors can play an important part of a combination therapy in attacking cancer.
Working with the knowledge that the CD44v6 protein acts as a co-receptor for receptor tyrosine kinases like MET and VEGFR-2 that drive pancreatic cancer, a group of German investigators at the Karlsruher Institut fur Technologie (KIT) say they've successfully tested a new peptide approach in mice that throws up a hurdle that can blunt and perhaps even stop the development of the disease. Read more >>
After sequencing the DNA of patients suffering from severe diarrhea and their healthy relatives, researchers at Michigan State say they have identified a new microbiome strategy for aiding patients by better balancing levels of healthy and sickening gut bacteria. Read more >>
POPULAR COMMENT THREADS
Researchers say that persistent and high inflammation in the brain affects connections relating to important symptoms that are currently difficult to treat, triggering up to a third of all cases of depression. And they believe their discovery can point to other therapeutic remedies for depression
Investigators at the University of Birmingham in the U.K. have published the results of a small but intriguing study that has highlighted the potential of Novo Nordisk's blockbuster diabetes drug Victoza (liraglutide) for NASH, an increasingly common liver disease.
Nanocarriers are microscopic synthetic particles that can deliver therapeutic drugs to a required area in the body. Now researchers say they have developed a new class of nanocarriers, prompting optimism in the long fight against aggressive cases of glioblastoma multiforme.
Investigators at The Ohio State University Comprehensive Cancer Center say they've nailed down fresh preclinical evidence that an experimental HDAC inhibitor can guard against muscle wasting in cancer cases.
Scientists at Sanford Burnham Prebys Medical Discovery Institute say that a new molecular machinery-targeting drug dubbed SBI-756 demonstrated preclinical evidence of success in a mouse model for melanoma.
Despite repeated assurances from rival camps that toxic loads of amyloid beta and tau are likely causes of Alzheimer's disease, no one is quite sure what is going on and clinical failures are routine. But investigators at UC San Diego School of Medicine say they have been garnering some preclinical clues that would suggest there could be a new pathway to follow in the clinic.
From Our Sister Sites
Siemens plans 7,000+ layoffs after disappointing healthcare performance Following a 13% reduction in profit at Siemens Healthcare during the previous quarter, the conglomerate is reportedly planning...
Sweden's Lund University is forming a med tech accelerator with an emphasis on digital health.